Herbs (Global Traditional) · Pacific Islands
Kava (Piper methysticum) (Piper methysticum)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Kava (Piper methysticum) is a Pacific Island plant containing kavalactones that modulate GABA neurotransmitter activity in the brain. These compounds primarily target GABA-A receptors and voltage-gated sodium channels to produce anxiolytic effects.
Kava (Piper methysticum) is a perennial shrub native to Polynesia, belonging to the Piperaceae family, with its dried rhizome (underground stem) used as the primary medicinal part. The rhizome is traditionally processed into aqueous extracts via cold maceration, while modern pharmaceutical extracts employ organic solvents like ethanol (yielding ~30% kavalactones) or acetone (~70% kavalactones) through percolation, agitation, or sonication methods.
The research dossier explicitly states that search results lack specific details on key human clinical trials, RCTs, or meta-analyses for kava, including PubMed PMIDs, study designs, sample sizes, or outcomes. No clinical efficacy or safety trial data is provided in the available sources.
No clinically studied dosage ranges for kava forms (extract, powder, standardized) are detailed in the available research. Extracts are standardized to 30% kavalactones (ethanolic) or 70% kavalactones (acetonic), but specific human dosing information is not provided. Consult a healthcare provider before starting any new supplement.
Kavalactones, comprising 30-70% of standardized kava extracts, primarily bind to GABA-A receptors and block voltage-gated sodium channels. Key compounds include kavain, dihydrokavain, and methysticin, which enhance GABAergic neurotransmission. These mechanisms collectively reduce neuronal excitability and promote anxiolytic effects without significant cognitive impairment.
Clinical research on kava shows limited high-quality human trials despite traditional use spanning centuries in Polynesia. Most available studies are small-scale or observational, lacking robust randomized controlled trial data. While traditional evidence suggests therapeutic applications for anxiety and ceremonial purposes, quantified clinical outcomes remain poorly documented. Current evidence quality is insufficient to establish definitive therapeutic efficacy claims.
Kava may cause hepatotoxicity, particularly with prolonged use or combination with alcohol and hepatotoxic medications. Common side effects include drowsiness, skin discoloration, and gastrointestinal upset. Kava can potentiate effects of CNS depressants, benzodiazepines, and alcohol, requiring careful monitoring. Contraindicated in pregnancy, nursing, and individuals with liver disease or depression.